Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-6901

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? ; volume:17 ; number:3 ; day:11 ; month:8 ; year:2017 ; pages:461-467 ; date:9.2017
Drugs in R & D ; 17, Heft 3 (11.8.2017), 461-467, 9.2017

Keyword: Krebs
Onkologie

Creator: Grassi, Paolo

Contributor: Verzoni, Elena
Ratta, Raffaele
Porcu, Luca
Prisciandaro, Michele
Mennitto, Alessia
Calareso, Giuseppina
Braud, Filippo De
Procopio, Giuseppe
SpringerLink (Online service)

DOI: 10.1007/s40268-017-0203-y

URN: urn:nbn:de:1111-201711295598

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Grassi, Paolo
Verzoni, Elena
Ratta, Raffaele
Porcu, Luca
Prisciandaro, Michele
Mennitto, Alessia
Calareso, Giuseppina
Braud, Filippo De
Procopio, Giuseppe
SpringerLink (Online service)

Other Objects (12)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Reversible Hypopigmentation with Pazopanib

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Related objects

Reset password